Netupitant Palonosetron Fdc Market

Netupitant - Palonosetron FDC - Global Market Opportunity Assessment Study, 2012 - 2018

  • Rep Id : TMRGL729
  • Published On : Oct 2012
  • No. of Pages : 44
  • Category : Pharmaceutical

Table of Content
 
1. Preface
    1.1. Report Description
    1.2. Research Methodology
           1.1.1. Therapeutic Classes
           1.1.2. Order of Entry into the Market
           1.1.3. Indications
           1.1.4. Dosage & Formulation Type
           1.1.1. Company Overview
           1.1.2. Business Strategy
           1.1.3. Financial Overview
           1.1.4. Products and Services
           1.1.5. Recent Developments
 
2. Executive Summary and Market Overview
 
3. Market Analysis
    3.1. Introduction: Chemotherapy Induced Nausea and Vomiting (CINV)
           3.1.1. Description
           3.1.2. Aetiology/Causes for CINV 
           3.1.3. Current Drug Treatment Available 
    3.2. CINV Market Size & Opportunity Scenario (1/2)
           3.2.1. Global CINV Market (USD Million), 2009 - 2015 
           3.2.2. CINV Market (USD Million), by Geography, 2009 – 2015
           3.2.3. Global CINV Patient Pool (Million), 2009 – 2015
           3.2.4. CINV Target Patient Pool, by Geography, 2009 - 2015
    3.3. Description of Netupitant - Palonosetron FDC 
    3.4. Mechanism of Action of Netupitant - Palonosetron FDC 
    3.5. Clinical Trials Detail 
           3.5.1. Clinical Trial Detail – 1
                    3.5.1.1. Trials Id - NCT01376297 
           3.5.2. Clinical Trial Detail – 2
                     3.5.2.1. Trials Id - NCT01339260 
    3.6. Unmet Needs in CINV Market 
    3.7. Factors influential to the sales of Netupitant - Palonosetron FDC 
    3.8. Sales Projection: Netupitant - Palonosetron FDC 
           3.8.1. Global Target Patient Pool 
           3.8.2. Global Forecasted Sales in $ in 000\'s
    3.9. SWOT Analysis 
           3.9.1. Strength
           3.9.2. Weakness
           3.9.3. Opportunity
           3.9.4. Threat
   3.10. Overall License Agreement for Netupitant - Palonosetron FDC
           3.10.1. Global
           3.10.2. United States
           3.10.3. Europe
           3.10.4. Australia
           3.10.5. UK & Ireland
           3.10.6. South Korea
  3.11. Company Profile – Helsinn Group